Compare Crispr Therapeutics AG (CRSP) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Hut 8 Corp — how do they compare? Crispr Therapeutics AG trades at $53.94 (market cap $5.23B), while Hut 8 Corp trades at $91.33 (market cap $10.94B). The key difference: Hut 8 Corp is far larger — about 2.1× Crispr Therapeutics AG's market cap, and Hut 8 Corp is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | HUT | |
|---|---|---|
Market Cap | $5.23B | $10.94B |
Sector | Health | Technology |
52-Week High | $76.78 | $133.02 |
52-Week Low | $44.34 | $21.37 |
Enterprise Value | $3.65B | $18.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
HUT trades at $90.77, up 5.97% on the day, amid a broader neocloud stock rally. The technical picture is bearish with resistance at $92 and support at $87. Fundamentally, the company reported a net loss of $226.15 million in 2025 despite revenue growth, with a negative net income margin of -188.59%. Recent news highlights a significant $26.6 billion contracted backlog and $7.5 billion in project financing for AI data center development, driving investor optimism about its strategic pivot.
The outlook is mixed: strong analyst buy ratings (93.75%) and a $165.11 price target suggest upside, but persistent losses, high valuation ratios, and execution risks on new projects pose challenges. The stock's near-term direction will hinge on translating its AI infrastructure backlog into profitable growth and achieving positive cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
